INCY Overview
Upcoming Projects (INCY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (INCY)
-
Q4: A second Prescriber check in on Opzelura in Atopic Dermatitis or nonsegmental vitiligo
Ticker: INCY
Executed On: Nov 21, 2024 at 03:30 PM EST -
Q4: Prescriber check in on Opzelura in Atopic Dermatitis or nonsegmental vitiligo
Ticker: INCY
Executed On: Nov 21, 2024 at 12:15 PM EST -
A Third Opinion: Diving into the topline results from the phase 3 inMIND clinical trial of Monjuvi (Tafasitamab) in patients with relapsed or refractory follicular lymphoma.
Ticker: INCY
Executed On: Oct 22, 2024 at 05:00 PM EDT -
A Third Look: Discussing the potential of axatilimab-csfr, recently approved and dubbed Niktimvo for patients with chronic graft-versus-host disease (cGVHD)
Tickers: SNDX, INCY
Executed On: Oct 22, 2024 at 04:00 PM EDT -
A Second Look: Discussing the potential of axatilimab-csfr, recently approved and dubbed Niktimvo for patients with chronic graft-versus-host disease (cGVHD)
Tickers: SNDX, INCY
Executed On: Oct 22, 2024 at 03:00 PM EDT -
A Second Opinion: Diving into the topline results from the phase 3 inMIND clinical trial of Monjuvi (Tafasitamab) in patients with relapsed or refractory follicular lymphoma.
Ticker: INCY
Executed On: Oct 22, 2024 at 07:30 AM EDT -
Diving into the topline results from the phase 3 inMIND clinical trial of Monjuvi (Tafasitamab) in patients with relapsed or refractory follicular lymphoma.
Ticker: INCY
Executed On: Oct 21, 2024 at 12:30 PM EDT -
Discussing the potential of axatilimab-csfr, recently approved and dubbed Niktimvo for patients with chronic graft-versus-host disease (cGVHD)
Tickers: SNDX, INCY
Executed On: Oct 17, 2024 at 03:00 PM EDT -
A third look: Prescriber check in on Opzelura in Atopic Dermatitis or nonsegmental vitiligo
Ticker: INCY
Executed On: Aug 19, 2024 at 03:00 PM EDT -
A second look: Prescriber check in on Opzelura in Atopic Dermatitis or nonsegmental vitiligo
Ticker: INCY
Executed On: Aug 16, 2024 at 03:00 PM EDT -
Prescriber check in on Opzelura in Atopic Dermatitis or nonsegmental vitiligo
Ticker: INCY
Executed On: Aug 12, 2024 at 02:00 PM EDT -
A Third Look: Discussing the potential of Povorcitinib, a JAK inhibitor in development by Incyte, for patients with Prurigo Nodularis (PN).
Ticker: INCY
Executed On: Mar 28, 2024 at 11:00 AM EDT -
A Third Look: Discussing the potential of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with Hurley stage 1 or 2 hidradenitis suppurativa.
Ticker: INCY
Executed On: Mar 26, 2024 at 05:30 PM EDT -
A Second Look: Discussing the potential of Povorcitinib, a JAK inhibitor in development by Incyte, for patients with Prurigo Nodularis (PN).
Ticker: INCY
Executed On: Mar 26, 2024 at 11:00 AM EDT -
A Second Look: Discussing the potential of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with Hurley stage 1 or 2 hidradenitis suppurativa.
Ticker: INCY
Executed On: Mar 25, 2024 at 03:00 PM EDT -
Discussing the potential of Povorcitinib, a JAK inhibitor in development by Incyte, for patients with Prurigo Nodularis (PN).
Ticker: INCY
Executed On: Mar 25, 2024 at 02:00 PM EDT -
Discussing the potential of twice-daily ruxolitinib cream 1.5% (Opzelura) in adult patients with Hurley stage 1 or 2 hidradenitis suppurativa.
Ticker: INCY
Executed On: Mar 21, 2024 at 09:30 AM EDT -
A Third View: Discussing the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio as treatments for non-segmental vitiligo
Tickers: ABBV, INCY
Executed On: Oct 26, 2023 at 12:00 PM EDT -
A Second View: Discussing the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio as treatments for non-segmental vitiligo
Tickers: ABBV, INCY
Executed On: Oct 20, 2023 at 01:00 PM EDT -
Discussing the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio as treatments for non-segmental vitiligo
Tickers: ABBV, INCY
Executed On: Oct 19, 2023 at 02:00 PM EDT -
A Third Look: Evaluating the topline results of the Phase 3 TRuE-AD3 clinical trial of Opzelura (Ruxolitinib Cream) in children with atopic dermatitis.
Ticker: INCY
Executed On: Sep 12, 2023 at 04:15 PM EDT -
A Second Look: Evaluating the topline results of the Phase 3 TRuE-AD3 clinical trial of Opzelura (Ruxolitinib Cream) in children with atopic dermatitis.
Ticker: INCY
Executed On: Aug 16, 2023 at 10:00 AM EDT -
Evaluating the topline results of the Phase 3 TRuE-AD3 clinical trial of Opzelura (Ruxolitinib Cream) in children with atopic dermatitis.
Ticker: INCY
Executed On: Jul 21, 2023 at 12:00 PM EDT -
Discussing the recent approval of Zynyz (Retifanlimab) from Incyte in merkel cell carcinoma (MCC).
Tickers: MRK, INCY
Executed On: Apr 18, 2023 at 02:00 PM EDT -
A Third Look: Discussing the potential use of povorcitinib (INCB54707) for patients with Hidradenitis Suppurativa currently in development by Incyte
Ticker: INCY
Executed On: Mar 10, 2023 at 11:30 AM EST -
A Second Look: Discussing the potential use of povorcitinib (INCB54707) for patients with Hidradenitis Suppurativa currently in development by Incyte
Ticker: INCY
Executed On: Mar 09, 2023 at 01:00 PM EST -
Discussing the potential use of povorcitinib (INCB54707) for patients with Hidradenitis Suppurativa currently in development by Incyte
Ticker: INCY
Executed On: Mar 08, 2023 at 01:00 PM EST -
A second look at the standard of care for chronic graft-versus-host disease and the future use of ibrutinib and ruxolitinib in the pediatric population
Tickers: INCY, ABBV, JNJ, SNY
Executed On: Oct 28, 2022 at 10:30 AM EDT -
A look at the standard of care for chronic graft-versus-host disease and the future use of ibrutinib and ruxolitinib in the pediatric population
Tickers: ABBV, JNJ, SNY, INCY
Executed On: Oct 26, 2022 at 12:00 PM EDT -
A third view: Digging into the P1/2 results and potential of Relay Therapeutics' FGFR2 inhibitor, RLY-4008, in cholangiocarcinoma.
Tickers: RLAY, INCY, Taiho Pharmaceuticals, QED Therapeutics
Executed On: Oct 14, 2022 at 02:00 PM EDT -
A second view: Digging into the P1/2 results and potential of Relay Therapeutics' FGFR2 inhibitor, RLY-4008, in cholangiocarcinoma
Tickers: RLAY, INCY, Taiho Pharmaceuticals, QED Therapeutics
Executed On: Oct 07, 2022 at 04:30 PM EDT -
A Third View: Discussing the FDA Approval of Oluminant for treatment of Alopecia Areata
Tickers: LLY, INCY
Executed On: Jun 23, 2022 at 03:00 PM EDT -
A Second View: Discussing the FDA Approval of Oluminant for treatment of Alopecia Areata
Tickers: LLY, INCY
Executed On: Jun 17, 2022 at 01:00 PM EDT -
Discussing the FDA Approval of Oluminant for treatment of Alopecia Areata
Tickers: LLY, INCY
Executed On: Jun 16, 2022 at 05:30 PM EDT -
A Second Opinion: Examining Incyte's Phase 3 TRuE-V data for Ruxolitinib Cream (Opzelura) in treating non-segmental vitiligo
Ticker: INCY
Executed On: May 13, 2022 at 02:00 PM EDT -
Examining Incyte's Phase 3 TRuE-V data for Ruxolitinib Cream (Opzelura) in treating non-segmental vitiligo
Ticker: INCY
Executed On: Apr 08, 2022 at 03:50 PM EDT -
Discussing the recently approved JAK Inhibitor Opzelura Cream (Ruxolitinib)
Ticker: INCY
Executed On: Mar 15, 2022 at 03:00 PM EDT
Upcoming & Overdue Catalysts (INCY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (INCY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
